Kinase inhibitors: A new class of antirheumatic drugs

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 245-250

  Kyttaris, Vasileios C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Janus kinases; Kinase inhibitors; Mitogen activated phosphokinase p38; Rheumatoid arthritis; Spleen tyrosine kinase

Indexed keywords

ADALIMUMAB; BARICITINIB; CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOSTAMATINIB; GLPG 0634; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PAMAPIMOD; PHOSPHOTRANSFERASE INHIBITOR; PLACEBO; PROTEIN KINASE SYK; PROTEIN KINASE TYK2; TALMAPIMOD; TOFACITINIB; UNCLASSIFIED DRUG; VX 509; VX 702;

ABDOMINAL PAIN; ANEMIA; ARTICLE; AUTOIMMUNITY; BRONCHITIS; CELLULITIS; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; KIDNEY FUNCTION; LIVER ABSCESS; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PLEURA EFFUSION; PYELONEPHRITIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 84872011053     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S25426     Document Type: Article

References (33)

1. Weinblatt ME, Trentham DE, Fraser PA, et al. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988;31:167-175.
2. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259.
3. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998;41:2196-2204.
4. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-2829.
5. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med. 2003;349:1907-1915.
6. Edwards JC, Szczepanski L, Szechinski J, et al. Effcacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572-2581.
7. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884-1894.
8. Baert F, Noman M, Vermeire S, et al. Infuence of immunogenicity on the long-term effcacy of infiximab in Crohn's disease. N Engl J Med. 2003;348:601-608.
9. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary defnition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727-735.
10. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429:403-417.
11. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature. 1994;372:739-746.
12. Beyaert R, Cuenda A, Vanden Berghe W, et al. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J. 1996;15:1914-1923.
13. Schett G, Tohidast-Akrad M, Smolen JS, et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum. 2000;43:2501-2512.
14. Nishikawa M, Myoui A, Tomita T, Takahi K, Nampei A, Yoshikawa H. Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum. 2003;48:2670-2681.
15. Alten RE, Zerbini C, Jeka S, et al. Effcacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. Ann Rheum Dis. 2010;69:364-367.
16. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the effcacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 2009;60:335-344.
17. Damjanov N, Kauffman RS, Spencer-Green GT. Effcacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009;60:1232-1241.
18. Genovese MC, Cohen SB, Wofsy D, et al. A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the effcacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis. J Rheumatol. 2011;38:846-854.
19. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. Drug Discov Today. 2010;15:517-530.
20. Pine PR, Chang B, Schoettler N, et al. Infammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007;124:244-257.
21. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58: 3309-3318.
22. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363:1303-1312.
23. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337-345.
24. Milici AJ, Kudlacz EM, Audoly L, Zwillich S, Changelian P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther. 2008;10:R14.
25. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and effcacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60: 1895-1905.
26. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012;64:970-981.
27. Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 2012;64:617-629.
28. Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507.
29. van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508-519.
30. Mariette X, Curtis JR, Lee EB, et al. Tofacitinib (CP-690,550), an oral janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical programme. Presented at the Annual European Congress of Rheumatology. Berlin, Germany, June 6-9, 2012.
31. Charles-Schoeman C, Wicker P, Sechtem U, et al. Cardiovascular safety fndings in rheumatoid arthritis patients treated with tofacitinib. Presented at the Annual European Congress of Rheumatology. Berlin, Germany, June 6-9, 2012.
32. van Vollenhoven RF, Fleischmann R, Cohen SB, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, or adalimumab versus placebo in patients with rheumatoid arthritis on background methotrexate: a Phase 3 study. Presented at the American College of Rheumatology Annual Meeting. Chicago, IL, November 4-9, 2011.
33. Fleischmann R, Spencer-Green GT, Fan F, et al. Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA). Presented at the American College of Rheumatology Annual Meeting. Chicago, IL, November 4-9, 2011.